Tevard Biosciences is pioneering tRNA therapeutics that modulate mRNA function to cure a broad range of genetic diseases—and open the possibility of treating multiple diseases with a single drug. Co-founded by renowned MIT and Whitehead Institute Professor Harvey Lodish and driven by a diverse team of industry and thought leaders, Tevard has already achieved proof of biology and mechanism in vivo. The company is currently raising funds to continue to advance multiple indications toward the clinic.